← Back to Search

Anti-epileptic drug

Cenobamate (Xcopri) for Seizures

Phase 1
Recruiting
Research Sponsored by SK Life Science, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or female subjects, from age 2 to less than 18 years at the time of informed consent
Minimum weight of 10.0 kilograms (kg) (22.0 pounds [lb])
Must not have
Evidence of significant hematological disease; white blood cell (WBC) count equal or less than 2500/μL (2.50 1E+09/L) or an absolute neutrophil count equal or less than 1000/μL (1.00 1E+09/L)
Any suicidal ideation with intent or without a plan within 6 months before Visit 2 in participants aged 6 and above
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 18 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a medication called cenobamate to see how it works in children who have a specific type of seizure. The study will look at how the drug moves through the body and how safe it is when taken over time. Cenobamate aims to calm overactive brain signals that cause these seizures.

Who is the study for?
This trial is for children and teens aged 2 to less than 18 with epilepsy characterized by partial-onset seizures. They must have been diagnosed at least 6 months prior, weigh over 10 kg, be on a stable dose of up to two antiepileptic drugs (excluding vagal nerve stimulators), and not have significant health issues like heart problems or severe infections.
What is being tested?
The study tests the drug Cenobamate (YKP3089) in young patients with epilepsy to understand how the body processes it after one dose and multiple doses. It aims to find out how much of the drug gets into the bloodstream and how long it stays there.
What are the potential side effects?
While specific side effects are not listed here, similar medications can cause drowsiness, dizziness, fatigue, coordination difficulties, changes in behavior or mood, allergic reactions or skin rashes. The trial will monitor for these and other potential adverse effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 2 and 17 years old.
Select...
I weigh at least 22 pounds.
Select...
I have epilepsy with partial-onset seizures.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My white blood cell count is low, or I have very few infection-fighting cells.
Select...
I have not had thoughts of harming myself in the last 6 months.
Select...
My ECG shows a QT interval outside the normal range.
Select...
I do not have any major health issues that could make it unsafe for me to participate in the study.
Select...
I am not pregnant or breastfeeding, and if of childbearing age, I agree to use effective birth control.
Select...
I haven't taken vigabatrin for 5 months and my eye test after stopping it was normal.
Select...
I have used emergency anxiety medication more than twice in the last month.
Select...
I haven't taken phenytoin or clobazam for at least 30 days.
Select...
I am scheduled for surgery during the study period.
Select...
I was hospitalized for a severe seizure within the last 6 months.
Select...
My neurological condition is getting worse over time.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
The area under the curve (AUC) of Xcopri after a single and multiple doses of Xcopri
The maximum plasma concentration (Cmax) after a single and multiple doses of Xcopri
Secondary study objectives
Safety - adverse events (AEs) reporting after a single and multiple doses of Xcopri

Side effects data

From 2022 Phase 3 trial • 1345 Patients • NCT02535091
23%
Somnolence
22%
Fatigue
12%
Balance disorder
8%
Nystagmus
7%
Diplopia
7%
Gait disturbance
6%
Nausea
6%
Decreased appetite
6%
Ataxia
5%
Vision blurred
5%
Headache
2%
Pneumonia
1%
Gynaecomastia
1%
Dysarthria
1%
Gastritis
1%
Intervertebral disc protrusion
1%
Intentional overdose
1%
Prostate cancer
1%
Corona virus infection
1%
Arterial haemorrhage
1%
Generalized tonic-clonic seizure
1%
Partial seizures with secondary generalisation
1%
Seizure
1%
Anger
1%
Suicide attempt
1%
Hypovolaemic shock
1%
Forearm fracture
1%
Generalised tonic-clonic seizure
1%
Vomiting
100%
80%
60%
40%
20%
0%
Study treatment Arm
YKP3089 and Phenytoin
YKP3089 and Phenobarbital
YKP3089 and Other AEDs

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Cohort IIbExperimental Treatment1 Intervention
Xcopri to be administered to ages 4 to \< 6 years not to exceed 400 mg/day.
Group II: Cohort IIaExperimental Treatment1 Intervention
Xcopri to be administered to ages 6 to \< 12 years not to exceed 400 mg/day.
Group III: Cohort IIIExperimental Treatment1 Intervention
Xcopri to be administered to ages 2 to \< 4 years not to exceed 400 mg/day.
Group IV: Cohort IExperimental Treatment1 Intervention
Xcopri to be administered to ages 12 to \< 18 years not to exceed 400 mg/day.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for epilepsy, such as Cenobamate, work by modulating voltage-gated sodium channels and enhancing GABAergic inhibition. These mechanisms are essential because they help stabilize neuronal membranes and increase inhibitory neurotransmission, reducing the likelihood of abnormal electrical activity that causes seizures. For epilepsy patients, this means better control over seizure frequency and severity, leading to improved quality of life and reduced risk of seizure-related complications.
Felbamate add-on therapy for drug-resistant focal epilepsy.

Find a Location

Who is running the clinical trial?

SK Life Science, Inc.Lead Sponsor
41 Previous Clinical Trials
8,913 Total Patients Enrolled
15 Trials studying Epilepsy
4,265 Patients Enrolled for Epilepsy
Marc Kamin, MDStudy DirectorSK Life Science, Inc.
9 Previous Clinical Trials
2,307 Total Patients Enrolled
4 Trials studying Epilepsy
537 Patients Enrolled for Epilepsy

Media Library

Cenobamate (YKP3089) (Anti-epileptic drug) Clinical Trial Eligibility Overview. Trial Name: NCT04903314 — Phase 1
Epilepsy Research Study Groups: Cohort III, Cohort IIb, Cohort I, Cohort IIa
Epilepsy Clinical Trial 2023: Cenobamate (YKP3089) Highlights & Side Effects. Trial Name: NCT04903314 — Phase 1
Cenobamate (YKP3089) (Anti-epileptic drug) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04903314 — Phase 1
~6 spots leftby Oct 2025